Skip to main content
Premium Trial:

Request an Annual Quote

KeyGene, Genalice Ink Licensing Deal

NEW YORK (GenomeWeb News) – Plant genomics firm KeyGene and startup bioinformatics company Genalice today announced a deal aimed at improving plant DNA analysis.

As part of the agreement, KeyGene will license Genalice MAP, a short-read alignment tool, which processes raw next-generation sequencing data into a small and easily manageable file for low-cost storage or further analysis.

"The breakthrough software solution … is a leap forward in improving our analysis pipeline and in staying ahead of competition," KeyGene CEO Arjen van Tunen said in a statement. "In addition, the strategic partnership with Genalice allows us to influence new functionalities within the product that will benefit our business."

Financial and other terms of the agreement were not disclosed.

Genalice is based in the Netherlands and launched late last year. Last month it said that it was awarded €200,000 ($275,000) for its participation in a European Union project to determine the causes of extreme aggressive behavior.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.